Evidence map›Paper›PMID 42605301›Full record

ArticleResearch and reports in urology2026

Metastatic Prostate Cancer: Impact of Site on Oncological Outcomes in Japanese Patients.

Kentaro Arinami, Keita Tsuboya, Kozue Ito, Shuhei Kondo, Yurie Takizawa, Yohei Ikeda, Gen Kawaguchi, Noboru Hara, Tsutomu Nishiyama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kentaro ArinamiDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Keita TsuboyaDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Kozue ItoDepartment of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Shuhei KondoDepartment of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Yurie TakizawaDepartment of Diagnostic Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Yohei IkedaDepartment of Diagnostic Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Gen KawaguchiDepartment of Radiation Oncology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Noboru HaraDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Tsutomu NishiyamaDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.ORCID 0000-0002-5684-8364

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To investigate the site of metastasis and progression to castration-resistant prostate cancer (CRPC) following treatment of patients with metastatic prostate cancer who were diagnosed and treated at our hospital. Methods: We retrospectively examined the metastasis status and treatment response of patients with metastatic prostate cancer who were histologically diagnosed between the opening of our hospital in June 2015 and March 2025. Results: A total of 139 patients with metastatic prostate cancer visited our hospital and were diagnosed with the condition. CRPC-free survival was significantly correlated with the bone metastasis volume (EOD 0 and 1 vs EOD 2 to 4) (P = 0.0000477), volume categories (P = 0.00196), risk categories (P = 0.00231), and PSA levels below/not below 0.2 ng/mL following ADT (P = 4.18 × 10 Discussion and conclusion: In our data on patients with metastatic prostate cancer, factors influencing the prognosis were: the extent of bone metastasis and responsiveness of PSA levels to initial treatments such as ADT. Factors such as GG at the time of biopsy or presence of lung metastases did not significantly impact the prognosis. Our data suggest that patients with lung metastases, but without bone metastases, may have a relatively favorable prognosis. New prognostic evaluation indicators are needed.

Indexed as

metastatic prostate cancermetastatic siteoncological outcomes

Identifiers

PMID42605301
PMCPMC13477658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.